The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
about
Insight to drug delivery aspects for colorectal cancerImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteAntibody-based delivery of IL4 to the neovasculature cures mice with arthritis.Production of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana.RNA-seq Profiles of Immune Related Genes in the Spleen of Necrotic Enteritis-afflicted Chicken LinesImmunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12.Immunocytokines for cancer treatment: past, present and future.Current role of anti-angiogenic strategies for glioblastoma.The emerging quest for the optimal angiostatic combination therapy.The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.Advances in Anticancer Protein Delivery Using Micro-/ Nanoparticles.Novel biotechnology approaches in colorectal cancer diagnosis and therapy.Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.Current progress in innovative engineered antibodies.DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.Targeting Fibronectin for Cancer Imaging and Therapy.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis.Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model.Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease.Emerging classes of armed antibody therapeutics against cancerAdvances and Prospects in Cancer Immunotherapy
P2860
Q26774682-152A9789-F5D9-4651-A720-AA5D9864C166Q28066935-D6814ECF-2B7B-49E0-B8B0-0CF3320B4E2AQ34083054-D0FCA700-C7E9-4A60-A80A-EEDF3B17A935Q35603066-5661D0B7-5B9D-4E31-9249-22254E8DF77CQ35760589-3DFC88F8-238B-4E16-80A8-8E01BF1FA9DDQ37485709-AAE16A60-46A5-4B07-88F3-A24B83EF21CFQ37559740-0CB2B0FF-7A78-47F3-9F4B-91D139425122Q37560208-AA70C9EF-8766-4A21-9922-340419CB4F94Q38244844-9F365D61-5D81-426E-80EF-7596759E7839Q38268453-5F100008-CF09-4780-9003-FC3A0008D80DQ38905573-256A728C-655D-48E5-A464-DD0F1DF0D54EQ38988662-376FDC54-ADDE-4613-B01F-F64FC43C5632Q39092873-550002C5-3625-4321-8A01-C266CC083468Q39151211-E6CE2478-3AE2-45C8-AC55-C6D7FA2B2724Q39185087-AEC3E886-4471-49C8-8C6A-690BB4C6BBF6Q39205186-4CD52ECA-B0EF-427C-90A0-291D10C93377Q40077818-378DCF2D-74D7-4145-8AE9-E3F6FB6B763BQ42202805-E3BB27E0-8FF1-44FD-98BB-18F4D3E4EB16Q45225869-629468E4-96EE-4A9D-B4F4-CAED48CA6C12Q47226151-9777B2EC-971D-47A6-9E10-2368CDABCE74Q47277628-EC071299-900F-425A-9EF7-2EBD871F362BQ48308048-1D5071C9-73E2-4847-86C3-D1799DE06871Q49819157-62CE0A80-D9E1-49E1-BFF9-06DFE1B0A14AQ50039410-E5B41119-6EFC-4B31-A77D-F6188E78DC42Q50073502-781DDE18-A78B-442A-907F-10548D9F39B1Q50592781-85B57CF9-4374-4AF9-B7B4-FCA159313E03Q50885364-26613952-5347-4A90-BD80-41EFE07A5327Q50962872-13BE5FE7-4B7B-4126-AC4B-0AAF13EBC84EQ53499740-89B1A20E-3968-46CB-8E64-971B9D365485Q57911948-0E950386-FCD2-4F4D-8AE6-BAFE6543F080Q59072375-68CAC0A9-4EDF-4CCD-A30A-239B30A91B8A
P2860
The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The antibody-based targeted de ...... three mouse models of cancer.
@en
The antibody-based targeted de ...... three mouse models of cancer.
@nl
type
label
The antibody-based targeted de ...... three mouse models of cancer.
@en
The antibody-based targeted de ...... three mouse models of cancer.
@nl
prefLabel
The antibody-based targeted de ...... three mouse models of cancer.
@en
The antibody-based targeted de ...... three mouse models of cancer.
@nl
P2860
P356
P1476
The antibody-based targeted de ...... three mouse models of cancer.
@en
P2093
Teresa Hemmerle
P2860
P304
P356
10.1002/IJC.28359
P50
P577
2013-08-10T00:00:00Z